|
1
|
Zernecke A, Weber KSC, Erwig LP, Kluth DC,
Schroppel B, Rees AJ and Weber C: Combinatorial model of chemokine
involvement in glomerular monocyte recruitment: role of CXC
chemokine receptor 2 in infiltration during nephrotoxic nephritis.
J Immunol. 166:5755–5562. 2001. View Article : Google Scholar
|
|
2
|
Miller RP, Tadagavadi RK, Ramesh G and
Reeves WB: Mechanisms of cisplatin nephrotoxicity. Toxins.
2:2490–2518. 2010. View Article : Google Scholar
|
|
3
|
Eliopoulos N, Zhao J, Bouchentouf M,
Forner K, Birman E, Yuan S, Boivin MN and Martineau D: Human
marrow-derived mesenchymal stromal cells decrease cisplatin
renotoxicity in vitro and in vivo and enhance survival of mice
post-intraperitoneal injection. Am J Physiol Renal Physiol.
299:F1288–F1298. 2010. View Article : Google Scholar
|
|
4
|
Fram RJ: Cisplatin and platinum analogues:
recent advances. Curr Opin Oncol. 4:1073–1079. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gonçalves GM, Zamboni DS and Câmara NO:
The role of innate immunity in septic acute kidney injuries. Shock.
34(Suppl 1): 22–26. 2010.
|
|
6
|
Matsushima H, Yonemura K, Ohishi K and
Hishida A: The role of oxygen free radicals in cisplatin-induced
acute renal failure in rats. J Lab Clin Med. 131:518–526. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Faubel S, Lewis EC, Reznikov L, Ljubanovic
D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA and
Edelstein CL: Cisplatin-induced acute renal failure is associated
with an increase in the cytokines interleukin (IL)-1β, IL-18, IL-6,
and neutrophil infiltration in the kidney. J Pharmacol Exp Ther.
322:8–15. 2007.
|
|
8
|
Mukaida N: Pathophysiological roles of
interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell
Mol Physiol. 284:L566–L577. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li F, Zhang X and Gordon JR:
CXCL8(3–73)K11R/G31P antagonizes ligand binding to the
neutrophil CXCR1 and CXCR2 receptors and cellular responses to
CXCL8/IL-8. Biochem Biophys Res Commun. 293:939–944. 2002.
|
|
10
|
Li F, Zhang X, Mizzi C and Gordon JR:
CXCL8(3–73)K11R/G31P antagonizes the neutrophil
chemoattractants present in pasteurellosis and mastitis lesions and
abrogates neutrophil influx into intradermal endotoxin challenge
sites in vivo. Vet Immunol Immunopathol. 90:65–77. 2002.
|
|
11
|
Zhao X, Li F, Town JR, Zhang X, Wang W and
Gordon JR: Humanized forms of the CXCR1/CXCR2 antagonist, bovine
CXCL8(3–74)K11R/G31P, effectively block ELR-CXC
chemokine activity and airway endotoxemia pathology. Int
Immunopharmacol. 7:1723–1731. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao X, Town JR, Li F, Zhang X, Cockcroft
DW and Gordon JR: ELR-CXC chemokine receptor antagonism targets
inflammatory responses at multiple levels. J Immunol.
182:3213–3222. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gordon JR, Li F, Zhang X, Wang W, Zhao X
and Nayyar A: The combined CXCR1/CXCR2 antagonist
CXCL8(3–74)K11R/G31P blocks neutrophil infiltration,
pyrexia, and pulmonary vascular pathology in endotoxemic animals. J
Leukoc Biol. 78:1265–1272. 2005.PubMed/NCBI
|
|
14
|
Zhao X, Town JR, Li F, Li W, Zhang X and
Gordon JR: Blockade of neutrophil responses in aspiration pneumonia
via ELR-CXC chemokine antagonism does not predispose to airway
bacterial outgrowth. Pulm Pharmacol Ther. 23:22–28. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao X, Town JR, Yang A, Zhang X, Paur N,
Sawicki G and Gordon JR: A novel ELR-CXC chemokine antagonist
reduces intestinal ischemia reperfusion-induced mortality, and
local and remote organ injury. J Surg Res. 162:264–273. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Waugh DJ and Wilson C: The interleukin-8
pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu X, Peng J, Sun W, Yang S, Deng G, Li
F, Cheng JW and Gordon JR: G31P, an antagonist against CXC
chemokine receptors 1 and 2, inhibits growth of human prostate
cancer cells in nude mice. Tohoku J Exp Med. 228:147–156. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wilson C, Purcell C, Seaton A, Oladipo O,
Maxwell PJ, O’Sullivan JM, Wilson RH, Johnston PG and Waugh DJ:
Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling
in metastatic prostate cancer cells confers resistance to
oxaliplatin through potentiation of nuclear factor-kappaB
transcription and evasion of apoptosis. J Pharmacol Exp Ther.
327:746–759. 2008. View Article : Google Scholar
|
|
19
|
Wilson C, Wilson T, Johnston PG, Longley
DB and Waugh DJ: Interleukin-8 signaling attenuates TRAIL- and
chemotherapy-induced apoptosis through transcriptional regulation
of c-FLIP in prostate cancer cells. Mol Cancer Ther. 7:2649–2661.
2008. View Article : Google Scholar
|
|
20
|
Kim YS, Moon JI, Kim DK, Kim SI and Park
K: Ratio of donor kidney weight to recipient bodyweight as an index
of graft function. Lancet. 357:1180–1181. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jüttner S, Wissmann C, Jons T, Vieth M,
Hertel J, Gretschel S, Schlag PM, Kemmner W and Hocker M: Vascular
endothelial growth factor-D and its receptor VEGFR-3: two novel
independent prognostic markers in gastric adenocarcinoma. J Clin
Oncol. 24:228–240. 2006.PubMed/NCBI
|
|
22
|
Moldobaeva A, Baek A, Eldridge L and
Wagner EM: Differential activity of pro-angiogenic CXC chemokines.
Microvasc Res. 80:18–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Katyal S, Oliver JH III, Peterson MS,
Ferris JV, Carr BS and Baron RL: Extrahepatic metastases of
hepatocellular carcinoma. Radiology. 216:698–703. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Siddik and Zahid H: Cisplatin: mode of
cytotoxic action and molecular basis of resistance. Oncogene.
22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
|
